 |
| |
| Oct-02-19 | Reiterated |
Chardan Capital Markets |
Buy |
$17 |
|
| Sep-25-19 | Initiated |
Chardan Capital Markets |
Buy |
$17 |
|
| Sep-18-19 | Initiated |
William Blair |
Outperform |
|
|
| May-31-19 | Initiated |
H.C. Wainwright |
Buy |
|
|
| Sep-01-17 | Initiated |
Citigroup |
Buy |
$11 |
|
| Mar-06-17 | Resumed |
Jefferies |
Buy |
$17 |
|
| May-12-16 | Resumed |
Jefferies |
Buy |
|
|
|
|
| Feb-17-20 11:15AM | Who Has Been Buying Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares? Simply Wall St. |
| Feb-05-20 08:00AM | Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia GlobeNewswire +5.18% |
| Jan-06-20 08:00AM | Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia GlobeNewswire |
| Dec-24-19 07:06AM | Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch +9.42% |
| Dec-19-19 03:07PM | Minerva shares fall on failed depression drug trial MarketWatch -17.85% |
| 09:35AM | Minerva Neurosciences Shelves Depression Drug Study After Failed Mid-Stage Trial Benzinga |
| 07:52AM | The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga |
| Dec-18-19 04:05PM | Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder GlobeNewswire |
| Dec-17-19 07:47PM | Hedge Funds Are Buying Minerva Neurosciences, Inc (NERV) Insider Monkey -5.11% |
| 08:29AM | Here's Why We're Not Too Worried About Minerva Neurosciences's (NASDAQ:NERV) Cash Burn Situation Simply Wall St. |
| Dec-04-19 04:05PM | SI-BONE Names Jeryl (Jeri) Hilleman to Board of Directors GlobeNewswire |
| Nov-21-19 12:21AM | Edited Transcript of NERV earnings conference call or presentation 4-Nov-19 1:30pm GMT Thomson Reuters StreetEvents |
| Nov-14-19 08:30AM | Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019 GlobeNewswire |
| Nov-11-19 12:10AM | Minerva Neurosciences, Inc (NERV): Are Hedge Funds Right About This Stock? Insider Monkey |
| Nov-04-19 07:30AM | Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates GlobeNewswire |
| Oct-28-19 08:30AM | Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019 GlobeNewswire |
| Oct-18-19 09:37AM | Does The Minerva Neurosciences, Inc. (NASDAQ:NERV) Share Price Tend To Follow The Market? Simply Wall St. |
| Oct-02-19 08:47AM | Company News For Oct 2, 2019 Zacks -12.96% |
| Oct-01-19 04:43PM | Investor Alert: Kaplan Fox Investigates Minerva Neurosciences, Inc. (NASDAQ: NERV) PR Newswire -26.32% |
| 09:23AM | Stocks - U.S. Steel Slumps, Spotify, Tesla Rise Premarket Investing.com |
| 08:49AM | Minerva's stock plunges to lead all premarket losers after cyber-attack delays enrollment in a phase 3 trial MarketWatch |
| 07:30AM | Minerva Neurosciences Announces Update for Three Clinical Trials GlobeNewswire |
| Sep-26-19 04:10PM | Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET GlobeNewswire |
| Sep-24-19 09:00AM | Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone GlobeNewswire |
| Sep-23-19 11:46AM | Zacks.com featured highlights include: ACM Research, GAIN Capital, Cutera, Columbus McKinnon and Minerva Zacks |
| Sep-20-19 09:10AM | Moving Average Crossover Alert: Minerva Neurosciences Zacks |
| Sep-19-19 09:38AM | 5 Stocks to Buy on New Analyst Coverage Zacks |
| Sep-03-19 10:53AM | What Kind Of Shareholder Appears On The Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Shareholder Register? Simply Wall St. |
| Aug-09-19 03:08AM | Edited Transcript of NERV earnings conference call or presentation 5-Aug-19 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-05-19 03:59PM | Minerva Neurosciences, Inc. (NERV) Q2 2019 Earnings Call Transcript Motley Fool +8.06% |
| 07:30AM | Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates GlobeNewswire |
| Jul-29-19 08:00AM | Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019 GlobeNewswire |
| Jul-04-19 11:36AM | Did Minerva Neurosciences, Inc. (NASDAQ:NERV) Insiders Buy Up More Shares? Simply Wall St. |
| Jun-28-19 03:19PM | Is Minerva Neurosciences, Inc (NERV) A Good Stock To Buy? Insider Monkey |
| Jun-24-19 11:00AM | Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial Benzinga +40.19% |
| 08:12AM | UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals MarketWatch |
| 07:30AM | Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia GlobeNewswire |
| Jun-23-19 05:30PM | Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant GlobeNewswire |
| Jun-12-19 08:30AM | Minerva Neurosciences to Present at JMP Securities Life Sciences Conference GlobeNewswire |
| May-29-19 08:30AM | Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019 GlobeNewswire |
| May-13-19 11:01AM | Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug Benzinga |
| 08:15AM | Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs GlobeNewswire |
| May-10-19 09:29AM | Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT Thomson Reuters StreetEvents |
| May-07-19 02:06PM | Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Simply Wall St. |
| May-06-19 12:00PM | Minerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript Motley Fool -5.15% |
| 07:35AM | Minerva Neurosciences: 1Q Earnings Snapshot Associated Press |
| 07:30AM | Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates GlobeNewswire |
| Apr-29-19 08:30AM | Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019 GlobeNewswire |
| Apr-11-19 08:30AM | Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia GlobeNewswire |
| Mar-18-19 11:41AM | Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT Thomson Reuters StreetEvents |
| 08:30AM | Minerva Neurosciences to Host Webcast Event on Schizophrenia GlobeNewswire |
| Mar-12-19 12:53PM | Minerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 07:46AM | Minerva Neurosciences: 4Q Earnings Snapshot Associated Press |
| 07:30AM | Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates GlobeNewswire |
| Mar-05-19 08:00AM | Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019 GlobeNewswire |
| Feb-05-19 08:30AM | Factors of Influence in 2019, Key Indicators and Opportunity within Wright Medical Group N.V, MSA Safety Incorporporated, Minerva Neurosciences, OSI, Argan, and Approach Resources New Research Emphasizes Economic Growth GlobeNewswire |
| Dec-20-18 11:32AM | How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own? Simply Wall St. |
| Nov-28-18 08:00AM | Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain GlobeNewswire |
| Nov-21-18 08:30AM | Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018 GlobeNewswire |
| Nov-19-18 08:00AM | Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers GlobeNewswire |
| Nov-16-18 04:49AM | Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy? Zacks |
| Nov-15-18 08:30AM | Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018 GlobeNewswire |
| Nov-09-18 08:10AM | New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -6.46% |
| Nov-07-18 08:30AM | Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018 GlobeNewswire +5.66% |
| Nov-05-18 11:10AM | Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT Thomson Reuters StreetEvents -9.74% |
| 07:47AM | Minerva Neurosciences: 3Q Earnings Snapshot Associated Press |
| 07:30AM | Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates GlobeNewswire |
| Oct-29-18 08:30AM | Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018 GlobeNewswire |
| Oct-16-18 08:10AM | Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +7.88% |
| Oct-10-18 01:17PM | Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying Simply Wall St. |
| Sep-05-18 06:07PM | J&J Submits NDA to the FDA for Depression Drug in Adults Zacks |
| Aug-23-18 08:23AM | The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero Benzinga |
| Aug-22-18 08:30AM | Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF) GlobeNewswire +8.38% |
| Aug-16-18 07:50AM | New Research Coverage Highlights EMCORE, Earthstone Energy, Pareteum, Lydall, Minerva Neurosciences, and Drive Shack Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Aug-04-18 05:19AM | Edited Transcript of NERV earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-02-18 10:12AM | Minerva Neurosciences: 2Q Earnings Snapshot Associated Press |
| 07:30AM | Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates GlobeNewswire |
| Jul-26-18 08:31AM | Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018 GlobeNewswire |
| Jul-25-18 08:01AM | Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel GlobeNewswire |
| Jul-17-18 04:06PM | Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors GlobeNewswire |
| May-30-18 08:31AM | Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018 GlobeNewswire |
| 08:30AM | Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018 GlobeNewswire |
| May-22-18 07:35AM | Recent Analysis Shows Capital Senior Living, Digital Realty Trust, Minerva Neurosciences, Zix, First Merchants, and PennantPark Investment Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
| May-17-18 08:21AM | Minerva Neurosciences shares rise 5% on trial results for schizophrenia drug MarketWatch +13.85% |
| 08:01AM | Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp... GlobeNewswire |
| 08:00AM | Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia GlobeNewswire |
| May-09-18 01:46PM | Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents |
| May-03-18 10:09AM | Minerva Neurosciences: 1Q Earnings Snapshot Associated Press -9.56% |
| 07:31AM | Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates GlobeNewswire |
| Apr-26-18 08:31AM | Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018 GlobeNewswire |
| 08:30AM | Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018 GlobeNewswire |
| Apr-09-18 08:31AM | Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder GlobeNewswire |
| 08:30AM | Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder GlobeNewswire |
| Mar-28-18 08:30AM | Detailed Research: Economic Perspectives on Altisource Residential, Sykes Enterprises, Gibraltar Industries, Silicon Laboratories, TC PipeLines, LP, and Minerva Neurosciences What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Mar-23-18 11:04AM | Will Minerva Neurosciences (NERV) Continue to Surge Higher? Zacks |
| Mar-15-18 08:31AM | Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22 GlobeNewswire |
| Mar-12-18 09:11PM | Edited Transcript of NERV earnings conference call or presentation 12-Mar-18 12:30pm GMT Thomson Reuters StreetEvents |
| 07:53AM | Minerva Neurosciences posts 4Q profit Associated Press |
| 07:31AM | Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates GlobeNewswire |
| 07:30AM | Minerva Neurosciences Inc to Host Earnings Call ACCESSWIRE |
|
|
|
|
| Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Race Geoff | EVP, CFO & CBO | Dec 17 | Sale | 7.10 | 5,826 | 41,365 | 205,044 | Dec 17 04:48 PM | | Luthringer Remy | CEO | Dec 17 | Sale | 7.10 | 2,412 | 17,125 | 49,040 | Dec 17 04:46 PM | | Ahlholm Frederick W | SVP, Chief Accounting Officer | Dec 17 | Sale | 7.10 | 1,557 | 11,055 | 15,223 | Dec 17 04:45 PM | | Reilly Joseph H. | SVP & Chief Operating Officer | Dec 17 | Sale | 7.10 | 2,724 | 19,340 | 26,225 | Dec 17 04:44 PM | | Russell Richard E. | President | Dec 12 | Sale | 7.42 | 3,113 | 23,098 | 33,770 | Dec 13 04:07 PM | | DOYLE WILLIAM F | Director | Jun 27 | Buy | 5.50 | 3,500 | 19,250 | 26,111 | Jul 01 04:43 PM | | VAN HEEK G JAN | Director | Jun 26 | Buy | 5.37 | 10,000 | 53,700 | 13,333 | Jun 27 04:30 PM | | HILLEMAN JERYL L | Director | Jun 26 | Buy | 5.25 | 1,000 | 5,250 | 1,000 | Jun 27 04:28 PM | | HASLER HANS PETER | Director | Jun 26 | Buy | 5.60 | 10,000 | 56,000 | 10,000 | Jun 27 04:28 PM | | Kupfer David | Director | Jun 26 | Buy | 5.55 | 10,000 | 55,500 | 219,188 | Jun 27 04:26 PM | | Index Venture Associates III L | 10% Owner | Jun 24 | Sale | 6.01 | 197,000 | 1,184,837 | 3,899,189 | Jun 26 04:12 PM | | Index Venture Associates III L | 10% Owner | Jun 20 | Sale | 4.34 | 33,575 | 145,759 | 4,096,189 | Jun 21 04:12 PM | | Index Venture Associates III L | 10% Owner | Jun 19 | Sale | 4.44 | 77,243 | 343,152 | 4,129,764 | Jun 21 04:12 PM | | Index Venture Associates III L | 10% Owner | Jun 18 | Sale | 4.44 | 49,675 | 220,522 | 4,207,007 | Jun 19 04:10 PM | | Index Venture Associates III L | 10% Owner | Jun 17 | Sale | 4.45 | 56,243 | 250,208 | 4,256,682 | Jun 19 04:10 PM | | Index Venture Associates III L | 10% Owner | Jun 14 | Sale | 4.50 | 25,169 | 113,188 | 4,312,925 | Jun 17 04:26 PM | | Index Venture Associates III L | 10% Owner | Jun 13 | Sale | 4.51 | 53,298 | 240,550 | 4,338,094 | Jun 17 04:26 PM | | Index Venture Associates III L | 10% Owner | Jun 12 | Sale | 4.57 | 26,901 | 122,989 | 4,391,392 | Jun 13 04:55 PM | | Index Venture Associates III L | 10% Owner | Jun 11 | Sale | 4.78 | 33,150 | 158,354 | 4,418,293 | Jun 13 04:55 PM | | Index Venture Associates III L | 10% Owner | May 20 | Sale | 6.08 | 200 | 1,215 | 4,451,443 | May 21 04:10 PM | | Index Venture Associates III L | 10% Owner | May 17 | Sale | 6.02 | 22,718 | 136,681 | 4,451,643 | May 21 04:10 PM | | Index Venture Associates III L | 10% Owner | May 16 | Sale | 6.37 | 44,836 | 285,673 | 4,474,361 | May 16 06:09 PM | | Index Venture Associates III L | 10% Owner | May 15 | Sale | 6.64 | 53,418 | 354,466 | 4,519,197 | May 16 06:09 PM | | Index Venture Associates III L | 10% Owner | May 14 | Sale | 7.05 | 36,574 | 258,022 | 4,572,615 | May 16 06:09 PM |
|
|
|
|
|
|
